Inuvair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, suppressing inflammatory gene expression and reducing airway swelling. Formoterol fumarate activates β2‑adrenergic receptors on bronchial smooth muscle, raising cyclic AMP levels and causing prolonged relaxation of the airways. Together they provide anti‑inflammatory and bronchodilatory effects that maintain airway patency.

The prescribed dose of Inuvair Nexthaler is determined by the treating physician based on the severity of the patient’s asthma or COPD, prior treatment response, and guideline recommendations. Patients should follow the specific dosing instructions provided by their healthcare professional and not adjust the dose without medical advice.

Safety data for Inuvair Nexthaler in pregnancy and lactation are limited. The decision to use the inhaler during pregnancy or while breastfeeding should be made by a healthcare professional after weighing the potential benefits for the mother against any possible risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Inuvair Nexthaler delivers a fixed‑dose combination of an inhaled corticosteroid and a long‑acting β2‑agonist, similar to other combination inhalers such as budesonide/formoterol or fluticasone/salmeterol. Its dry‑powder formulation may offer convenient dosing without propellants, and the specific pharmacokinetic profile of beclometasone and formoterol provides effective anti‑inflammatory and bronchodilator action comparable to alternative products.

Inuvair Nexthaler should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the device away from moisture, direct sunlight and heat sources. Do not expose the inhaler to freezing temperatures, and ensure the mouthpiece remains clean and dry between uses.

The inhaler is a dry‑powder device. The patient should open the mouthpiece, exhale fully away from the inhaler, place the mouthpiece between the lips, and inhale sharply and deeply to ensure the powder is drawn into the lungs. After inhalation, the patient should hold their breath for about 10 seconds, then exhale slowly. The device should be cleaned as instructed in the patient information leaflet.

Serious adverse reactions, although rare, can include paradoxical bronchospasm, adrenal suppression leading to systemic steroid effects, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden worsening of breathing, signs of infection, unusual fatigue, or any symptoms suggestive of an allergic response.

Inuvair Nexthaler is contraindicated in patients with known hypersensitivity to beclometasone dipropionate, formoterol fumarate, or any component of the inhaler. It should also be avoided in individuals who have experienced a severe allergic reaction to other inhaled corticosteroid/long‑acting β2‑agonist combinations. Patients with uncontrolled cardiovascular disease should use the product only under close medical supervision.